ECM
KZR

Endurant Capital Management’s Kezar Life Sciences KZR Stock Holding History

Endurant Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,947
Closed -$988K – 68
2022
Q1 		$988K Buy
+5,947
New +$854K 0.26% 57

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Endurant Capital Management's KZR Position: Q2 2022 in Review

Endurant Capital Management sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 5,947 shares — an estimated $988K sold.

Endurant Capital Management first reported a position in KZR in Q1 2022 and held it in 1 quarter. The position peaked at $988K in Q1 2022. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

  • Endurant Capital Management reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
  • Endurant Capital Management sold 5,947 Kezar Life Sciences shares in Q2 2022, an estimated $988K.
  • Endurant Capital Management first reported a position in Kezar Life Sciences in Q1 2022 and held it in 1 quarter.
  • Endurant Capital Management's Kezar Life Sciences position peaked at $988K in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.